[1] The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization[J].Tuber Lung Dis,1994,75(3):180-181. [2] Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al.Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey[J]. JAMA, 1998, 280(18):1569-1575. [3] 夏愔愔,詹思延.国内抗结核药物不良反应发生率的综合分析[J].中华结核和呼吸杂志,2007,30(6):419-423. [4] The Global Plan to Stlp TB. 2006-2015.Actions for life: towards a world free of tuberculosis[J].Int J Tuberc Lung Dis, 2006, 10(3):240-241. [5] Zignol M, Hosseini MS, Wright A, et al.Global incidence of multi-drug resistant tuberculosis[J].J Infect Dis, 2006,194(4):479-485. [6] Lee KL,PryorDB,Harrell FE Jr,et al.Predicting outcome in coronary disease. Statistical models versus expert clinicians[J]. Am JMed,1986,80( 4) : 553-560. [7] 邱济海,侯巍,杨亦德,等.抗结核药物所致肝损害的特点及危险因素研究[J].中国高等医学教育,2017(01):136-137. [8] 李文红,王芳,付莹,等.肺结核药物性肝损害的相关因素分析[J].临床肺科杂志,2016,21(11):2097-2100. [9] Devarbhavi H,Dierkhising R,Kremers WK,et al.Single-center experience with drug-induced liver injury from India: causes,out-come,prognosis,and predictors of mortality[J].Am J Gastroenterol,2010,105(11):2396-2404. [10] 杨莹. 肺结核病患者抗结核肝损害92例临床分析[J].中国热带医学,2014,14(7): 862-865. [11] 倪艳,邹永胜,刘泽明.肺结核患者抗结核药物引起肝损害的临床特点分析[J].国外医药抗生素分册,2014,35(2):85-87. [12] 张娟娟,王云霞,刘振扬,等.影响肺结核病病人防治效果的社会因素分析[J].中国社会医学杂志,2018,35(3):256-258. [13] Gaude GS,Chaudhury A,Hattiholi J.Drug-induced hepatitis pa-tients[J]. J Family Med Prim Care,2015,4(2):238-243. [14] Begun M, Newall AT, Marks GB,et al.Contact tracing of tuberculosis: a systematic review of transmission modelling studies[J]. PLoS One, 2013, 8(9): e72470. [15] Andrews JR, Morrow C, Walensky RP, et al.Integrating social contact and environmental data in evaluating tuberculosis transmission in a South African township[J]. J Infect Dis, 2014, 210(4): 597-603. |